Kisho

Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy

thromboangiitis obliterans - Clinical Profile, Genes & Research | Kisho | Kisho

Rare Disease

thromboangiitis obliterans

MONDO:0008889

Also known as:Buerger's Diseasepresenile gangrenethromboangiitis obliterans [Buerger's disease]

Find Clinical TrialsTrials

Overview

A rare inflammatory non-necrotizing vascular disease affecting the small- and medium-sized arteries and veins of the upper and lower extremities characterized by endarteritis and vaso-occlusion due to occlusive thrombus development. The development and progression of the disease is consistently associated with exposure to tobacco.

GeneticsAutosomal recessive

TreatmentsNo approved treatments · 9 in pipeline

Clinical Trials4 registered · 2 recruiting

Clinical Presentation

Built from Human Phenotype Ontology (HPO) phenotype annotations and GeneReviews clinical descriptions. Features represent findings documented across known cases — not an exhaustive list of possible symptoms.

Features include very common findings: Sensory neuropathy, Vasculitis, Arterial thrombosis, and Gangrene and others; and common findings: Acrocyanosis, Arthralgia, Paresthesia, and Intermittent claudication and others. 19 total HPO annotations.

Organ System	Phenotype Count	Example Features
Brain and nerves	5	Pain, Sensory neuropathy, Paresthesia

Diagnosis

Biomarker and diagnostic research for thromboangiitis obliterans has been reported in the published literature.

Treatment

Compiled from FDA-approved drug records, orphan drug designations, and FDA Adverse Event Reporting System (FAERS) safety data. GeneReviews management guidance is included where available.

No approved treatments are currently available for thromboangiitis obliterans. An additional 9 compounds hold orphan drug designation.

Orphan Drug Designations

While no drugs are FDA-approved specifically for thromboangiitis obliterans, some of the following designated compounds may be used off-label in clinical practice. Treatment decisions should be made in consultation with a specialist familiar with this condition.

The following drugs have received orphan drug designation from the FDA for thromboangiitis obliterans. Orphan designation reflects regulatory interest and does not indicate approval for treatment.

Brand Name	Generic Name	Sponsor

Prognosis

Phenotype severity distribution: 5 very common features, 6 common features.

Estimated prevalence: 1-5 in 10,000 (Uncommon).

Research Landscape

Sourced from ClinicalTrials.gov and PubMed. Publication types are classified using NLM-curated article metadata; research type breakdowns reflect the nature of published work for this disease.

4 clinical trials registered, 2 recruiting. Interventions under study include drug therapy, biologic therapy, and other interventions. Pipeline includes 1 PHASE4, 1 PHASE3, 1 PHASE1. Research is sponsored by a mix of industry and academic institutions.

107 publications have been identified in PubMed for thromboangiitis obliterans. Research spans Case Report / Case Series (23%), Review / Meta-Analysis (19%), and Clinical Trial Publication (16%).

Research Type	Count	% of Total
Patient case studies	25

Data assembled from 7 of 12 sources · Last updated Sep 19, 2026, 4:29 PM UTC

MONDOHPOClinicalTrials.govFDAPubMedHGNCClinVarClinGenGeneReviewsOrphanetOMIMRUSP

Medical References

External Resources

OMIM

Online Mendelian Inheritance in Man

OMIM:211480

Orphanet

European rare disease database

Orphanet:36258

GARD

Genetic and Rare Diseases Info Center

GARD:5969

Questions for Your Care Team

→Should my partner and I meet with a genetic counselor to discuss carrier status and family planning?
→Are any of the 4 active clinical trials a good fit for my situation?
→With 9 compounds in the orphan drug pipeline, which are furthest along in development and which clinical trials should I be aware of?
→Are there specialists or centers of excellence for this condition in my area?
→Is there a patient registry I should consider joining?

← Back to All Diseases

Kisho

thromboangiitis obliterans

Overview

Clinical Presentation

Diagnosis

Treatment

Orphan Drug Designations

Prognosis

Research Landscape

Medical References

External Resources

OMIM

Orphanet

GARD

Questions for Your Care Team

Questions for Your Care Team

Explore clinical features

Clinical Trials

Recent Publications

Latest News & Developments

Outcomes of endovascular revascularization of upper limb thromboangiitis obliterans via palmar arch angioplasty.

thromboangiitis obliterans

Overview

Clinical Presentation

Diagnosis

Treatment

Orphan Drug Designations

Prognosis

Research Landscape

Medical References

External Resources

OMIM

Orphanet

GARD

Related Diseases

Questions for Your Care Team

Questions for Your Care Team

Explore clinical features

Clinical Trials

Recent Publications

Latest News & Developments

Outcomes of endovascular revascularization of upper limb thromboangiitis obliterans via palmar arch angioplasty.